NASDAQ:NYMX Nymox Pharmaceutical (NYMX) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.19▼$0.4752-Week Range N/AVolume932,700 shsAverage Volume94,622 shsMarket Capitalization$18.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Nymox Pharmaceutical (NASDAQ:NYMX) StockNymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.Read More NYMX Stock News HeadlinesAugust 29, 2023 | markets.businessinsider.comNymox Reports Completion of $2 Million Private PlacementJuly 18, 2023 | finanznachrichten.deNymox Pharmaceutical Corporation: Nymox Reports on U.S. Patent IssuancesSeptember 24, 2023 | Legacy Research (Ad)Watch SHOCKING Footage of AI Facility with Ties to Elon MuskI recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.July 18, 2023 | finance.yahoo.comNymox Reports on U.S. Patent IssuancesJuly 16, 2023 | venturebeat.comThe Committee to Restore Nymox Shareholder Value Soundly Rebuts Injurious Allegations Made by Nymox Pharmaceutical Corp Current ManagementJuly 12, 2023 | finance.yahoo.comNymox Announces Appointment Of Patrick Doody as Vice President and Member of the Board of Directors of NymoxJuly 9, 2023 | venturebeat.comRebuttal Letters Issued to Shareholders of NYMOX PHARMACEUTICAL CORP (“NYMX-Q”)July 8, 2023 | finanznachrichten.deNymox Pharmaceutical Corporation: NYMOX UpdateSeptember 24, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.July 7, 2023 | financialpost.comNYMOX UpdateJuly 6, 2023 | investorplace.comWhy Is Nymox Pharmaceutical (NYMX) Stock Down 18% Today?July 6, 2023 | seekingalpha.comNymox Pharmaceutical receives potential delisting notice from NasdaqJuly 6, 2023 | msn.comNYMX Tanks after Receiving Delisting NoticeJuly 5, 2023 | financialpost.comNymox Delisting from NASDAQJune 30, 2023 | finance.yahoo.comNYMX - Nymox Pharmaceutical CorporationJune 28, 2023 | thestreet.comNymox Pharmaceutical (NYMX) Stock Down After Disappointing Enlarged Prostate Treatment Test ResultsJune 15, 2023 | fool.comNymox Pharmaceutical (NASDAQ: NYMX)May 10, 2023 | finanznachrichten.deNymox Pharmaceutical Corporation: Nymox Provides Current UpdateApril 3, 2023 | finance.yahoo.comNymox Provides Corporate UpdateMarch 21, 2023 | finance.yahoo.comNymox Announces Appointment of Christopher R. Riley as Chief Financial OfficerMarch 15, 2023 | finance.yahoo.comNymox Officially Granted Extension to Regain Listing RequirementsMarch 6, 2023 | finance.yahoo.comOne Nymox Pharmaceutical Corporation (NASDAQ:NYMX) insider upped their stake by 32% in the previous yearFebruary 15, 2023 | finance.yahoo.comNymox Announces NYMOZARFEX Marketing Application is Accepted For ReviewJanuary 6, 2023 | finance.yahoo.comNYMOX Appeals Deficiency LetterDecember 5, 2022 | finance.yahoo.comNYMOX Announces New Marketing Submission for NYMOZARFEX™ for BPHNovember 25, 2022 | financialpost.comMay 2023 Market Cap Requirement UpdateSeptember 27, 2022 | finance.yahoo.comA Nymox Pharmaceutical Corporation (NASDAQ:NYMX) insider increased their holdings by 32% last yearSee More Headlines Receive NYMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address NYMX Company Calendar Last Earnings11/14/2014Today9/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NYMX CUSIPN/A CIK1018735 Webwww.nymox.com Phone(800) 936-9669Fax514-332-2227Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,589.50% Return on Assets-117.25% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / BookN/AMiscellaneous Outstanding Shares90,510,000Free Float41,637,000Market Cap$18.10 million OptionableOptionable Beta0.64 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Paul Averback DABP (Age 72)M.D., Founder, Chairman, CEO & Pres Comp: $660kMr. Randall J. Lanham Esq. (Age 59)J.D., Gen. Counsel, Sec., COO & Director Comp: $496.45kMs. Lin DoddQA and Compliance Mang.Mr. Christopher R. RileyChief Financial OfficerKey CompetitorsBiomericaNASDAQ:BMRAMyMD PharmaceuticalsNASDAQ:MYMDNavidea BiopharmaceuticalsNYSE:NAVBTrinity BiotechNASDAQ:TRIBOncoCyteNASDAQ:OCXView All Competitors NYMX Stock - Frequently Asked Questions How were Nymox Pharmaceutical's earnings last quarter? Nymox Pharmaceutical Co. (NASDAQ:NYMX) released its quarterly earnings data on Friday, November, 14th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The biopharmaceutical company had revenue of $0.08 million for the quarter. What other stocks do shareholders of Nymox Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Biocept (BIOC), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and CTI BioPharma (CTIC). What is Nymox Pharmaceutical's stock symbol? Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX." How much money does Nymox Pharmaceutical make? Nymox Pharmaceutical (NASDAQ:NYMX) has a market capitalization of $0.00. The biopharmaceutical company earns $-6,580,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. How can I contact Nymox Pharmaceutical? Nymox Pharmaceutical's mailing address is BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2. The official website for the company is www.nymox.com. The biopharmaceutical company can be reached via phone at (800) 936-9669, via email at info@nymox.com, or via fax at 514-332-2227. This page (NASDAQ:NYMX) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nymox Pharmaceutical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.